USA flag logo/image

An Official Website of the United States Government

NOVEL INHIBITORS OF BRAIN ISCHEMIA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66722
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
NS045421
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
COGNOSCI, INC.
79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709-2076
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: NOVEL INHIBITORS OF BRAIN ISCHEMIA
Agency: HHS
Contract: 1R43NS045421-01A1
Award Amount: $284,008.00
 

Abstract:

DESCRIPTION (provided by applicant): Stroke is a leading cause of death and disability in the United States affecting approximately 750,000 individuals each year. Stroke is characterized by a partial or complete lack of blood flow to a region of the brain that becomes deprived of both oxygen and nutrients and becomes the core of the ischemic, inffacted region. The timely re-establishment of blood flow to ischemic brain by use of thrombolytic agents is a current treatment strategy for acute stroke. The efficacy of this approach, however, is limited by an increased risk for intracerebral hemorrhage (ICH). It was shown that selective inhibition of the intrinsic coagulation pathway, while maintaining the extrinsic coagulation mechanisms, might be efficacious in restoring vascular patency while preventing increased risk for intracerebral hemorrhage. We have previously shown that the recombinant Kunitz proteinase inhibitor (KPI) domain of the amyloid g-protein precursor (APP) is a potent inhibitor of factors XIa and IXa of the intrinsic coagulation pathway, and displays little effect on the extrinsic coagulation pathway and its processes. We propose that the selective inhibitory activity of this KPI domain may be well suited for treatment of acute ischemic brain injury. In Phase I, we will measure the effect of treatment with synthetic KPI domain to reduce fibrin deposition and improve behavioral performance in a mouse model for focal ischemic injury.

Principal Investigator:

Michael P. Vitek

Business Contact:

Michael Vitek
9197650028
MIKEVITEK@COGNOSCI.COM
Small Business Information at Submission:

COGNOSCI, INC.
COGNOSCI, INC. BOX 12076, 2 DAVIS DR RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 562208520
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No